5α-Reductase inhibitor
class of medications with antiandrogenic effects used primarily in the treatment of enlarged prostate and scalp hair loss
5α-Reductase inhibitors (5-ARIs), also known as dihydrotestosterone (DHT) blockers, are a class of medications with antiandrogenic effects which are used primarily in the treatment of enlarged prostate and scalp hair loss. They are also sometimes used to treat excess hair growth in women and as a component of hormone therapy for transgender women.
These agents inhibit the enzyme 5α-reductase, which is involved in the metabolic transformations of a variety of endogenous steroids. 5-ARIs are most known for preventing conversion of testosterone, the major androgen sex hormone, to the more potent androgen dihydrotestosterone (DHT), in certain androgen-associated disorders.
Medical uses
5-ARIs are clinically used in the treatment of conditions that are exacerbated by DHT:
Mild-to-moderate benign prostatic hyperplasia and lower urinary tract symptoms
Pattern hair loss in both men and women
5-ARIs can be used in the treatment of hirsutism in women. The usefulness of 5-ARIs for the potential treatment of acne is uncertain. 5-ARIs are sometimes used as antiandrogens in feminizing hormone therapy for transgender women to help reduce body hair growth and scalp hair loss.
They have also been explored in the treatment and prevention of prostate cancer. While the 5-ARI finasteride reduces the cancer risk by about a third, it also increases the fraction of aggressive forms of prostate cancer. Overall, there does not seem to be a survival benefit for prostate cancer patients under finasteride.
The public source identifies “5α-Reductase inhibitor” as class of medications with antiandrogenic effects used primarily in the treatment of enlarged prostate and scalp hair loss. This brief keeps that definition visible, then builds a research path around 5α-Reductase, inhibitor and class.
Why this record matters
A short description can identify a subject without explaining its stakes. For “5α-Reductase inhibitor”, the useful work is to connect “class of medications with antiandrogenic effects used primarily in the treatment of enlarged prostate and scalp hair loss” to the records capable of establishing context and consequence.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Jul 23, 2026. The linked authority identifier is Q4639645. None of the 0 selected statements returned an explicit reference.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “5α-Reductase inhibitor”, its source revision and the description used here.
- Expand the search: follow 5α-Reductase inhibitor primary sources, 5α-Reductase inhibitor archive and 5α-Reductase research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “5α-Reductase inhibitor”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “5α-Reductase inhibitor” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.